Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia

Craig Wallington-Beddoe; Vicki Xie; Daochen Tong; Jason Powell; Alexander Lewis; Lorena Davies; Stuart Pitson; Kenneth Bradstock; Linda Bendall

doi:10.1111/bjh.15097

Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia

Craig Wallington-Beddoe, Vicki Xie, Daochen Tong, Jason Powell, Alexander Lewis, Lorena Davies, Stuart Pitson, Kenneth Bradstock, Linda Bendall

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Sphingosine 1-phosphate (S1P) is generated from the phosphorylation of sphingosine by sphingosine kinase 1 (SPHK1) or sphingosine kinase 2 (SPHK2) (Pyne et al, 2016). Overexpression of SPHK1 has indisputable tumour-promotingproperties (Pyne & Pyne, 2010) and is associated with imatinib resistance in chronic myeloid leukaemia (Bonhoure et al, 2008; Marfe et al, 2011) and daunorubicin and cytarabine resistance in acute myeloid leukaemia cells (Sobue et al, 2008; Powell et al, 2017). We recently reported the involvement of SPHK2 in acute lymphoblastic leukaemia (ALL) (Wallington-Beddoe et al, 2014) and here we describe a rolefor SPHK1.

Original language	English
Pages (from-to)	443-447
Number of pages	5
Journal	British Journal of Haematology
Volume	184
Issue number	3
DOIs	https://doi.org/10.1111/bjh.15097
Publication status	Published - 1 Feb 2019

Keywords

Leukaemia
novel therapies
sphingosine kinase

Access to Document

10.1111/bjh.15097Licence: In Copyright

Cite this

@article{3255a18be4c841d1937787a8b3191abb,

title = "Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia",

abstract = "Sphingosine 1-phosphate (S1P) is generated from the phosphorylation of sphingosine by sphingosine kinase 1 (SPHK1) or sphingosine kinase 2 (SPHK2) (Pyne et al, 2016). Overexpression of SPHK1 has indisputable tumour-promotingproperties (Pyne & Pyne, 2010) and is associated with imatinib resistance in chronic myeloid leukaemia (Bonhoure et al, 2008; Marfe et al, 2011) and daunorubicin and cytarabine resistance in acute myeloid leukaemia cells (Sobue et al, 2008; Powell et al, 2017). We recently reported the involvement of SPHK2 in acute lymphoblastic leukaemia (ALL) (Wallington-Beddoe et al, 2014) and here we describe a rolefor SPHK1.",

keywords = "Leukaemia, novel therapies, sphingosine kinase",

author = "Craig Wallington-Beddoe and Vicki Xie and Daochen Tong and Jason Powell and Alexander Lewis and Lorena Davies and Stuart Pitson and Kenneth Bradstock and Linda Bendall",

year = "2019",

month = feb,

day = "1",

doi = "10.1111/bjh.15097",

language = "English",

volume = "184",

pages = "443--447",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "BLACKWELL PUBLISHERS INC",

number = "3",

}

TY - JOUR

T1 - Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia

AU - Wallington-Beddoe, Craig

AU - Xie, Vicki

AU - Tong, Daochen

AU - Powell, Jason

AU - Lewis, Alexander

AU - Davies, Lorena

AU - Pitson, Stuart

AU - Bradstock, Kenneth

AU - Bendall, Linda

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Sphingosine 1-phosphate (S1P) is generated from the phosphorylation of sphingosine by sphingosine kinase 1 (SPHK1) or sphingosine kinase 2 (SPHK2) (Pyne et al, 2016). Overexpression of SPHK1 has indisputable tumour-promotingproperties (Pyne & Pyne, 2010) and is associated with imatinib resistance in chronic myeloid leukaemia (Bonhoure et al, 2008; Marfe et al, 2011) and daunorubicin and cytarabine resistance in acute myeloid leukaemia cells (Sobue et al, 2008; Powell et al, 2017). We recently reported the involvement of SPHK2 in acute lymphoblastic leukaemia (ALL) (Wallington-Beddoe et al, 2014) and here we describe a rolefor SPHK1.

AB - Sphingosine 1-phosphate (S1P) is generated from the phosphorylation of sphingosine by sphingosine kinase 1 (SPHK1) or sphingosine kinase 2 (SPHK2) (Pyne et al, 2016). Overexpression of SPHK1 has indisputable tumour-promotingproperties (Pyne & Pyne, 2010) and is associated with imatinib resistance in chronic myeloid leukaemia (Bonhoure et al, 2008; Marfe et al, 2011) and daunorubicin and cytarabine resistance in acute myeloid leukaemia cells (Sobue et al, 2008; Powell et al, 2017). We recently reported the involvement of SPHK2 in acute lymphoblastic leukaemia (ALL) (Wallington-Beddoe et al, 2014) and here we describe a rolefor SPHK1.

KW - Leukaemia

KW - novel therapies

KW - sphingosine kinase

UR - http://www.scopus.com/inward/record.url?scp=85040772947&partnerID=8YFLogxK

U2 - 10.1111/bjh.15097

DO - 10.1111/bjh.15097

M3 - Article

SN - 0007-1048

VL - 184

SP - 443

EP - 447

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this